Software of these information is restricted through the early character of the study results. It's unclear if constructive recurrence-cost-free survival results in CheckMate 274 will translate into improved cancer-certain survival. When response premiums to immune checkpoint inhibition in urothelial carcinoma is lower, individuals that achieve a re